Discontinued — last reported Q4 '17
Keurig Dr Pepper Indefinite-Lived Research and Development Assets decreased by 0.2% to $22.56B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from $22.54B to $22.56B. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates active investment in future technology, while a decrease may signal project completion or impairment.
These are acquired in-process research and development (IPR&D) projects that have not yet reached technological feasibil...
Common in technology and pharmaceutical sectors following M&A activity.
indefinite_lived_rd_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $22.61B | $22.55B | $22.55B | $22.62B | $22.54B | $22.07B | $21.99B | $22.12B | $22.22B | $22.14B | $22.11B | $22.11B | $22.00B | $21.99B | $22.53B | $22.54B | $22.73B | $22.71B | $22.59B | $22.56B |
| QoQ Change | — | -0.3% | +0.0% | +0.3% | -0.4% | -2.1% | -0.3% | +0.6% | +0.5% | -0.4% | -0.1% | -0.0% | -0.5% | -0.1% | +2.4% | +0.1% | +0.8% | -0.1% | -0.5% | -0.2% |
| YoY Change | — | — | — | — | -0.3% | -2.1% | -2.5% | -2.2% | -1.4% | +0.3% | +0.5% | -0.0% | -1.0% | -0.7% | +1.9% | +2.0% | +3.3% | +3.3% | +0.3% | +0.1% |